Chancroid medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 27: | Line 27: | ||
#The treatment was not used as instructed | #The treatment was not used as instructed | ||
#The H. ducreyi strain causing the infection is resistant to the prescribed antimicrobial. | #The H. ducreyi strain causing the infection is resistant to the prescribed antimicrobial. | ||
*Clinical resolution of fluctuant [[lymphadenopathy]] is slower than that of ulcers and might require needle aspiration or incision and drainage, despite otherwise successful therapy. Although needle aspiration of buboes is a simpler procedure, incision and drainage might be preferred because of reduced need for subsequent drainage procedures. | *Clinical resolution of fluctuant [[lymphadenopathy]] is slower than that of ulcers and might require needle aspiration or incision and drainage, despite otherwise successful therapy. Although needle aspiration of [[buboes]] is a simpler procedure, incision and drainage might be preferred because of reduced need for subsequent drainage procedures. | ||
===Treatment of Sex Partners=== | ===Treatment of Sex Partners=== |
Revision as of 16:37, 22 January 2016
Chancroid Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Chancroid medical therapy On the Web |
American Roentgen Ray Society Images of Chancroid medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The mainstay of therapy for chancroid is antimicrobial therapy. Azithromycin and Ceftriaxone are preferred because these agents offer the advantage of single dose therapy. Ceftriaxone is the drug of choice for pregnant women. Patients with HIV may require longer and repeated courses of therapy.
Medical Therapy
Successful treatment for chancroid cures the infection, resolves the clinical symptoms, and prevents transmission to others.
Antimicrobial Regimen
- Chancroid[1]
- Preferred Regimen (1): Azithromycin 1 g PO in a single dose
- Preferred Regimen (2): Ceftriaxone 250 mg IM in a single dose
- Preferred Regimen (3): Ciprofloxacin 500 mg PO bid for 3 days
- Preferred Regimen (4): Erythromycin base 500 mg PO tid for 7 days
- Note (1): Patients should be tested for Human Immunodeficiency Virus (HIV) infection at the time chancroid is diagnosed. If the initial test results were negative, a serologic test for syphilis and HIV infection should be performed 3 months after the diagnosis of chancroid.
- Note (2): Avoid ciprofloxacin among pregnant and lactating women due to risk of toxicity. Ceftriaxone may be considered among pregnant women.
- Note (3): HIV-positive patients should be monitored more closely due to high risk of treatment failure. Repeated or longer regimens may be required.
Follow-up
- Patients should be re-examined 3–7 days after initiation of therapy. If treatment is successful, ulcers usually improve symptomatically within 3 days and objectively within 7 days after therapy. If no clinical improvement is evident, the clinician must consider whether:
- The diagnosis is correct
- The patient is coinfected with another STD
- The patient is infected with HIV
- The treatment was not used as instructed
- The H. ducreyi strain causing the infection is resistant to the prescribed antimicrobial.
- Clinical resolution of fluctuant lymphadenopathy is slower than that of ulcers and might require needle aspiration or incision and drainage, despite otherwise successful therapy. Although needle aspiration of buboes is a simpler procedure, incision and drainage might be preferred because of reduced need for subsequent drainage procedures.
Treatment of Sex Partners
- sex partners of patients with chancroid should be examined and treated if they had sexual contact with the patient during the 10 days preceding the patient’s onset of symptoms.[2]
References
- ↑ Workowski, Kimberly A.; Bolan, Gail A. (2015-06-05). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 64 (RR-03): 1–137. ISSN 1545-8601. PMID 26042815.
- ↑ Workowski, Kimberly A.; Bolan, Gail A. (2015-06-05). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 64 (RR-03): 1–137. ISSN 1545-8601. PMID 26042815.